Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiyo Aims at Sales of Over ¥50 Bil. with 227 MRs in FY2009
June 22, 2009
- R&D NEWS IN BRIEF
June 22, 2009
- Top-Four Generic Firms' Business Grows by Leaps and Bounds
June 22, 2009
- Gov't to Consider Patent Rights on Treatment Regimens
June 22, 2009
- BUSINESS NEWS IN BRIEF
June 22, 2009
- 52nd JDS Annual Meeting
June 22, 2009
- Ultmarc to Hire More Healthcare Professionals to Provide More Customer-Oriented Services
June 22, 2009
- Larger-Scale, Dose-Finding PII Studies Necessary for Anticoagulants: Dr C.M. Gibson
June 22, 2009
- Give Incentives to Those Who Settle Prices Earlier: Mr Bessho
June 22, 2009
- New Antithrombotic Drugs That Solve Dilemma of Thrombotic Events and Hemorrhagic Events Needed: Prof. Goto
June 22, 2009
- Mediceo Paltac to Invest in Drug Wholesaler in China
June 22, 2009
- Sales of Ethical Drugs Up 2.4% in FY2008 Compared to FY2007
June 22, 2009
- Production of Drugs May Be Negatively Affected by Healthcare Reform: YANO Research
June 22, 2009
- Tadalafil Improves PAH Patients' Exercise Capacity: Eli Lilly, United Therapeutics
June 22, 2009
- Wyeth to Improve RA Patients' Access to Biologics
June 22, 2009
- Eli Lilly Begins Two Global PIII Trials of Solanezumab
June 22, 2009
- Teijin to Create Its Own Marketing System in Asia
June 22, 2009
- Pfizer Japan Offers "No-Smoking Allowance" to Employees
June 22, 2009
- Prograf in Combination with MMF Approved in the US: Astellas
June 22, 2009
- Health Minister Opposed to ¥220 Bil. Cut in Social Security Spending
June 22, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…